Double Blind Study of Propranolol for Migraine Prophylaxis

Diamond, Seymour; Medina, José Luis Valdez

doi:10.1111/j.1526-4610.1976.hed1601024.x

Cited by 111 publications

(57 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Throughout my professional career I conducted research, including early studies on the use of propranolol. 39 With Jose Medina, we reported on the efficacy of indomethacin on cluster headache variant. 40 The discovery of propranolol's efficacy in migraine was incidental.…”

Section: United States Of Americamentioning

confidence: 97%

Introduction – The History of Headache

Diamond

Franklin

2015

Headache and Migraine Biology and Management

Self Cite

View full text Add to dashboard Cite

Section: United States Of Americamentioning

confidence: 97%

Introduction – The History of Headache

Diamond

Franklin

2015

Headache and Migraine Biology and Management

Self Cite

View full text Add to dashboard Cite

“…This report prompted numerous clinical trials, with the eventual approval of propranolol for migraine prophylaxis in 1976. Approval was gained on the results of two studies involving 104 patients: Doctor Jose Medina and I reported on 62 evaluable patients [Diamond and Medina, 1976], and an unpublished report of John Graham on 42 cases treated with propranolol. It is amazing that to receive approval from the FDA during our current climate of regulation, evidence must be presented from double-blind studies that enrolled more than 1,000 patients.…”

Section: B-blockersmentioning

confidence: 99%

Evolution of migraine drugs

Diamond

2007

Drug Development Research

Self Cite

View full text Add to dashboard Cite

Headache is an ancient malady that has affected every age and country. As such, the quest for relief has been recorded for more than 6,000 years. In modern times, new remedies as well as those based in ancient herbal remedies have been investigated and initiated into the regimen of headache therapies. During the past five decades, several breakthroughs, such as the approval of propranolol for the indication of migraine prophylaxis, have empowered headache research. The introduction of the triptans during the 1990 s spearheaded a resurgence of interest in headache by researchers and clinicians, and the pharmaceutical industry. It is hoped that this renewed quest for headache relief will flourish, benefiting the millions of sufferers throughout the world. Drug Dev Res 68: 270-275, 2007.

show abstract

“…Their use is supported by a good body of evidence from several placebo-controlled trials. [8][9][10][11][12][13] However, they have a disadvantage of significant side effects, such as sedation, decreased blood pressure and, especially in women, weight gain, which can make adherence to treatment a problem for many patients. 14 The success rate for beta-blockers is around 50%, with half of the patients experiencing significant decreases in the number and severity of migraine attacks.…”

Section: Topiramate In Migraine Preventionmentioning

confidence: 99%

Topiramate in Migraine Prevention

Diener¹

2006

European Neurological Review

View full text Add to dashboard Cite

Migraine is one of the most frequent forms of headache. It is estimated that 6-8% of all men and 12-14% of all women suffer from migraine. [1][2][3][4] The lifetime-prevalence in women is >25%. Before puberty the frequency of migraine is 4-5%. Boys and girls are affected equally. The highest incidence of migraine attacks occurs between the 35th and 45th years of life. During this phase of life women are affected three times more frequently than men. Migraine attacks lead to severe, frequently unilateral pulsating and pounding headaches, increasing with physical activity. 5 This can lead to a severe disruption in quality of life and the World Health Organization (WHO) has rated migraine as one of the top 20 leading causes of disability worldwide. 6 The individual attacks are accompanied by a loss of appetite (almost always), nausea (80%), vomiting (40-50%), light sensitivity (photophobia 60%) noise sensitivity (phonophobia 50%) and odour hypersensitivity (10%). If the headaches are unilateral they can change sides within an attack or from attack to attack. The duration of the attacks, depending on the definition of the International Headache Society, varies between four and 72 hours. 5 In children the attacks are shorter and can also occur without headaches, and with only severe nausea, vomiting and giddiness. 6 M i g r a i n e P r o p h y l a x i sThe pharmacological treatment of acute migraine attacks is based on the 5-HT1B/1D agonists (triptans), non-opioid analgesics and non-steroidal antiinflammatory drugs (NSAIDs). If the patient suffers from three or more migraine attacks per month, migraine attacks regularly last longer than 72 hours and if the attack frequency increases and the intake of analgesics or antimigraine agents occurs on more than 10 days per month, then prophylactic treatment is recommended. Pharmacological prophylaxis is also indicated for migraine attacks that do not respond to acute therapy or if side effects render acute therapy intolerable.The aim of prophylaxis is to reduce the frequency, severity and duration of migraine attacks and to prevent the development of medication overuse. Migraine prophylaxis is considered effective if headache frequency is reduced by at least 50%. P h a r m a c o l o g i c a l P r o p h y l a x i s o f C h r o n i c M i g r a i n eIn Europe, beta-blockers (e.g. propranolol and metoprolol) are the most widely prescribed drugs for the prevention of migraine. Although the anti-epileptic drug (AED) sodium valproate has also been widely used in an off-label setting for migraine prophylaxis, the approval of topiramate represented the first AED to be indicated for migraine prevention. The tricyclic antidepressant amitriptyline, the calcium channel blocker flunarizine and the serotonin antagonist methysergide have also been used in the prophylaxis setting. Despite evidence of efficacy, the mechanism or site of action of these drugs is uncertain. Cortical spreading depression (CSD) has been implicated in migraine and as a headache trigger. In experimental animals CSD ...

show abstract

Double Blind Study of Propranolol for Migraine Prophylaxis

Cited by 111 publications

References 2 publications

Introduction – The History of Headache

Introduction – The History of Headache

Evolution of migraine drugs

Topiramate in Migraine Prevention

Contact Info

Product

Resources

About